proteinuria/sarkom

Linket gemmes på udklipsholderen

ArtiklerKliniske forsøgPatenter

Vælg sorteringstype

Side 1 fra 50 resultater

Kaposi Sarcoma in the Genital Area in a Kidney Transplant Patient: A Case Report and Literature Review.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

BACKGROUND Kaposi sarcoma (KS) is a cancer with an incidence in patients after transplantation (Tx) that is 500 times greater than that in the healthy population. The risk of KS increases significantly during therapy, especially when immunosuppressive therapy with cyclosporine A (CsA) is used. Most

[Acquired Fanconi-de Toni-Debre syndrome due to therapy for Ewing's sarcoma in 5-years old boy].

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

We present a 5-years old boy with acquired Fanconi-de Toni-Debre syndrome being a effect of therapy for Ewing's sarcoma. At the age of 3 years, this boy was diagnosed as suffering from Ewing sarcoma of his right femur. The boy received a course of 8-month pre-surgery (6 VIDE--Vincristine,

Systemic amyloidosis associated with pleomorphic sarcoma of the spleen and remission of nephrotic syndrome after removal of the tumor.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

We report a case of a 57-year-old woman who was diagnosed with a systemic AA amyloidosis associated with a pleomorphic sarcoma of the spleen. Although the association and causality between chronic inflammatory states and systemic AA amyloidosis have been well established, the evidence linking solid

Phase II trial of merbarone in soft tissue sarcoma. A Southwest Oncology Group study.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

Thirty-seven patients with advanced soft tissue sarcoma were treated with merbarone utilizing a daily intravenous schedule for five days. Only one partial response was observed in the thirty-three evaluable patients. The major toxicities were renal, with elevation of creatinine and/or proteinuria,

Ifosfamide nephropathy in patients with sarcoma.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

BACKGROUND Ifosfamide is an alkylating agent, frequently used in the treatment of sarcoma. Major side effects of ifosfamide are classified as nephropathy, neuropathy, and hematologic complications. The aim of present study was to determine the frequency and severity of ifosfamide nephropathy in

Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

Objective: To analyze the efficacy and safety of apatinib in the treatment of stage IV osteogenic sarcoma after chemotherapy failure through a single-arm, prospective, and open clinical phase II study. Methods: Information on 34 patients with stage IV osteogenic sarcoma treated with

Proteinuria after conversion to sirolimus in renal transplant recipients.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

Sirolimus (SRL) is a new, potent immunosuppressive agent. More recently, proteinuria has been reported as a consequence of sirolimus therapy, although the mechanism has remained unclear. We retrospectively examined the records of 25 renal transplant patients, who developed or displayed increased

Efficacy and safety of the VEGFR2 inhibitor Apatinib for metastatic soft tissue sarcoma: Chinese cohort data from NCT03121846.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

There is no standard treatment for stage IV soft tissue sarcoma (STS) after the failure of Adriamycin-based chemotherapy. This phase II study (NCT03121846) assessed the efficacy and safety of apatinib (YN968D1), a new tyrosine kinase inhibitor that targets VEGFR-2, for patients with

Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

Apatinib (YN968D1) is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2). We conducted a single-arm, nonrandomized phase II study (NCT03121846) to assess the efficacy and safety of apatinib in patients with stage IV sarcoma. We recruited 64 patients

Cediranib phase-II study in children with metastatic alveolar soft-part sarcoma (ASPS).

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

Alveolar soft-part sarcoma (ASPS), a rare vascular sarcoma with a clinically indolent course, frequently presents with metastases. Vascular endothelial growth factor (VEGF) is a promising therapeutic target. In a phase-II trial of the VEGF receptor inhibitor cediranib for adults with

Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

Background: There is an unmet need for markers predicting the outcome of patients with advanced soft tissue sarcoma (STS) treated with pazopanib. Since toxicity might be related to the anti-tumor activity of the drug, the aim of this study was to determine whether pazopanib-induced

Efficacy and safety of Apatinib in stage IV sarcomas: experience of a major sarcoma center in China.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

OBJECTIVE This study was conducted to review the efficacy and safety of Apatinib in stage IV sarcoma patients who failed previous chemotherapy. METHODS The clinical information on 16 patients with stage IV sarcomas who failed in prior chemotherapy and subsequently received Apatinib treatment was

Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

OBJECTIVE Pazopanib, an oral multikinase angiogenesis inhibitor, prolongs progression-free survival in adults with soft tissue sarcoma (STS). A phase I pharmacokinetic and pharmacodynamic study of two formulations of pazopanib was performed in children with STS or other refractory solid

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

PURPOSE Given the importance of angiogenesis in soft tissue sarcoma (STS), pazopanib, an oral angiogenesis inhibitor that targets vascular endothelial growth factor receptor and platelet-derived growth factor receptor, was explored in patients with advanced STS. PATIENTS AND METHODS Patients with

Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

Alveolar soft-part sarcoma (ASPS) is a rare soft-tissue sarcoma that is unresponsive to chemotherapy. Cediranib, a tyrosine-kinase inhibitor, has shown substantial activity in ASPS in non-randomised studies. The Cediranib in Alveolar Soft Part Sarcoma (CASPS) study was designed to

Tidligere
1
2
3
4
Næste

Deltag i vores
facebook-side

Herbal & Natural Medicine

Den mest komplette database med medicinske urter understøttet af videnskab

Arbejder på 55 sprog
Urtekurer, der understøttes af videnskab
Urtegenkendelse ved billede
Interaktivt GPS-kort - tag urter på stedet (kommer snart)
Læs videnskabelige publikationer relateret til din søgning
Søg medicinske urter efter deres virkninger
Organiser dine interesser og hold dig opdateret med nyhedsundersøgelser, kliniske forsøg og patenter

Skriv et symptom eller en sygdom, og læs om urter, der kan hjælpe, skriv en urt og se sygdomme og symptomer, den bruges mod.
* Al information er baseret på offentliggjort videnskabelig forskning